Denali Therapeutics
Update in progressDNLI (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Denali Therapeutics is a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases. Its pipeline includes Eclitasertib (SAR443122/DNL758), a RIPK1 inhibitor; BIIB122/DNL151, a LRRK2 inhibitor for Parkinson’s; TAK-594/DNL593 for frontotemporal dementia; DNL126 for Sanfilippo A; DNL310 for Hunter syndrome. It also develops Enzyme Transport Vehicle and OTV programs (DNL952, DNL111, DNL622) and Abeta-targeting DNL921. Formerly SPR Pharma; founded 2013 in South San Francisco.
Company score
- Sentiment
- -0.05
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.07
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Ryan J. Watts Ph.D.
- Founded2013
- Employees503
- Websitewww.denalitherapeutics.com
Identifiers
- ISINUS24823R1059
- FIGIBBG008P7F869
- LEI549300ZTQ2HO18L3Q830
- CUSIP24823R105
- CIK0001714899